Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Evangelos Terpos, MD PhD, Ramón García-Sanz, MD PhD, Kazuyuki Shimizu, MD, Wolfgang Willenbacher, MD PhD, Anthony Glennane, MD, Tian Dai, PhD, Walraud Pasteiner, PhD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 606.

https://doi.org/10.1182/blood-2019-127290

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms

Keertik Fulzele, PhD, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Tomoaki Mori, MD PhD, Shrikanta Chattopadhyay, MBBS, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 1802.

https://doi.org/10.1182/blood-2019-131213

Published: 2019

Journal Articles

Myeloma bone disease: from biology findings to treatment approaches

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Meletios A. Dimopoulos

Blood (2019) 133 (14): 1534–1539.

https://doi.org/10.1182/blood-2018-11-852459

Published: 2019

Journal Articles

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Quanhong Sun, PhD, Peng Zhang, PhDMD, Juraj Adamik, PhD, Konstantinos Lontos, MD, Valentina Marchica, MS, Nicola Giuliani, MD PhD, Rebecca W. Silbermann, MD, G. David Roodman, MD PhD, Deborah Lynn Galson, PhD

Blood (2018) 132 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2018-99-119677

Published: 2018

Journal Articles

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Adam J Olszewski, MD, Peter Barth, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 709.

https://doi.org/10.1182/blood-2018-99-110739

Published: 2018

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

The Gfi1-SphK1 Axis Regulates the Growth and Survival of Myeloma Cells

Daniela Nicoleta Petrusca, PhD, Evgeny Berdyshev, PhD, Patrick Mulcrone, PhD, Colin D. Crean, BS, Judith L Anderson, BS, Quanhong Sun, PhD, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2018) 132 (Supplement 1): 5615.

https://doi.org/10.1182/blood-2018-99-119507

Published: 2018

Journal Articles

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Blood (2018) 132 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2018-99-117293

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Emerging Clinical Concepts for Personalized Therapy in Multiple Myeloma; Systemtic Review

Faiza Hassan Warraich, MD, Sami Ullah Warraich, MBBS, Azka Latif, MD, Vikas Kapoor, MD, Faisal Akbar, MD, Ali McBride, PharmD,MS, Ahmad Iftikhar, MD, Pavan Tenneti, MD, Adeela Mushtaq, MD, Raahem Nayab Zafar, BS, Hafiz Muhammad Fazeel, MD, Syeda Sabeeka Batool, MBBS, Zabih Warraich, MD, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5411.

https://doi.org/10.1182/blood.V130.Suppl_1.5411.5411

Published: 2017

Journal Articles

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Rebecca Silberman, MD, Denise Toscani, PhD, Judith L Anderson, Nicola Giuliani, MD PhD, Xiang-Qun Xie, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4421.

https://doi.org/10.1182/blood.V130.Suppl_1.4421.4421

Published: 2017

Journal Articles

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Gabriel M. Pagnotti, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1775.

https://doi.org/10.1182/blood.V130.Suppl_1.1775.1775

Published: 2017

Journal Articles

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Attaya Suvannasankha, MD, Colin D Crean, Douglas R Tompkins, Jesus Delgado-Calle, PhD, Teresita M Bellido, PhD, G. David Roodman, MD PhD, John M Chirgwin, PhD

Blood (2016) 128 (22): 4439.

https://doi.org/10.1182/blood.V128.22.4439.4439

Published: 2016

Journal Articles

RANK-RANKL Mediated Bone Destruction in B-Cell Acute Lymphoblastic Leukemia

Sujeetha A. Rajakumar, MSc, Eniko Papp, PhD, Ildiko Grandal, MSc, Daniele Merico, PhD, Careesa C. Liu, MSc, Bedilu Allo, PhD, Lucia Zhang, Marc Grynpas, PhD, Mark D. Minden, MD PhD, Johann K. Hitzler, MD, Cynthia J. Guidos, PhD, Jayne S. Danska, PhD

Blood (2016) 128 (22): 908.

https://doi.org/10.1182/blood.V128.22.908.908

Published: 2016

Journal Articles

The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma (MM)

Tito R. Mendoza, PhD, Amylou C. Dueck, PhD, Qiuling Shi, PhD, Haijun Ma, PhD, Jeffrey Zhang, PhD, Yi Qian, PhD, Charles S. Cleeland, PhD

Blood (2015) 126 (23): 4495.

https://doi.org/10.1182/blood.V126.23.4495.4495

Published: 2015

NARROW

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms

Myeloma bone disease: from biology findings to treatment approaches

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

The Gfi1-SphK1 Axis Regulates the Growth and Survival of Myeloma Cells

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Emerging Clinical Concepts for Personalized Therapy in Multiple Myeloma; Systemtic Review

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

RANK-RANKL Mediated Bone Destruction in B-Cell Acute Lymphoblastic Leukemia

The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only